Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 12/07/2025 am IST			5-day change	1st Jan Change
18.17 ^USD	-4.69%		-0.38%	-85.06%

01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	CI
01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	CI

Sarepta Therapeutics Shares Rise After Upgrade From Scotiabank

Published on 07/06/2025 at 00:13

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	01/07	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	01/07	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Benchmark	30/06	CI
Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths	25/06	MT
FDA investigates patient deaths after treatment with Sarepta's gene therapy	25/06	RE
FDA investigates patient deaths after treatment with Sarepta's gene therapy	25/06	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	20/06	MT
Sarepta Therapeutics Shares Decline After Downgrade From William Blair	20/06	MT
The Two-Week Ticking Clock	20/06
William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform	20/06	MT
Analyst recommendations: Apple, Dow, Coinbase, Comcast, The Gap…	20/06
Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100	18/06	MT
TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62	18/06	MT
A Rate Decision in a War Drumbeat	18/06
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research…	18/06

Chart Sarepta Therapeutics, Inc.

Duration

Period

SRPT: Dynamic Chart

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,372

Sector

Pharmaceuticals

Calendar

30/07 - Q2 2025 Earnings Release (Projected)

More about the company